Cover Image
市場調查報告書

男性性腺功能低下症 : 開發平台分析

Male Hypogonadism - Pipeline Review, H2 2016

出版商 Global Markets Direct 商品編碼 232815
出版日期 內容資訊 英文 106 Pages
訂單完成後即時交付
價格
Back to Top
男性性腺功能低下症 : 開發平台分析 Male Hypogonadism - Pipeline Review, H2 2016
出版日期: 2016年07月27日 內容資訊: 英文 106 Pages
簡介

男性性腺功能低下症的主要症狀、有倦怠感、身體的發熱、不孕、肌肉量的減少、骨質疏鬆症。男性性腺功能低下症容易發病的環境、有HIV/AIDS、柯林菲特氏症、卡爾曼氏症候群、睪丸的負傷、睡眠呼吸中止症等。

本報告提供男性性腺功能低下症治療藥的開發情形的相關調查、開發中產品的概要、臨床實驗的各階段的產品概要、主要企業簡介、藥物簡介、開發中產品的最新趨勢等。

簡介

  • 調查範圍

男性性腺功能低下症概要

治療藥的開發

  • 開發中產品的概要
  • 開發中產品比較分析

男性性腺功能低下症:企業開發中的治療藥

男性性腺功能低下症:開發中產品概況

  • 後期階段的產品
  • 臨床階段的產品
  • 初期階段的產品
  • 開發階段不明的產品

男性性腺功能低下症:企業開發中的產品

男性性腺功能低下症治療藥的開發企業

  • Antares Pharma, Inc.
  • BIOCAD
  • Clarus Therapeutics, Inc.
  • Diurnal Limited
  • EndoCeutics, Inc.
  • Ferring International Center S.A.
  • Forendo Pharma Limited
  • Lipocine Inc.
  • M et P Pharma AG
  • Merck & Co., Inc.
  • Mereo Biopharma Group Limited
  • Millennium Pharmaceuticals, Inc.
  • Monosol Rx, LLC
  • Pantarhei Bioscience BV
  • Repros Therapeutics Inc.

男性性腺功能低下症:治療藥的評估

  • 單劑產品
  • 各標靶
  • 各作用機制
  • 各給藥途徑
  • 各分子類型

藥物簡介

  • BGS-649
  • corifollitropin alfa
  • enclomiphene
  • fispemifene
  • follitropin alfa
  • Kisspeptin-10
  • Libidua
  • LPCN-1111
  • MSS-722
  • T-2
  • TAK-448
  • TBS-1
  • Testavan
  • testosterone
  • testosterone
  • testosterone
  • testosterone
  • testosterone enanthate
  • testosterone undecanoate
  • testosterone undecanoate
  • testosterone undecanoate
  • testosterone undecanoate
  • testosterone undecanoate

男性性腺功能低下症:最近的開發平台趨勢

男性性腺功能低下症:暫停中的計劃

男性性腺功能低下症:開發中止的產品

男性性腺功能低下症:產品開發的里程碑

  • 主要消息和新聞稿

附錄

本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

目錄
Product Code: GMDHC8305IDB

Summary

Global Markets Direct's, 'Male Hypogonadism - Pipeline Review, H2 2016', provides an overview of the Male Hypogonadism pipeline landscape.

The report provides comprehensive information on the therapeutics under development for Male Hypogonadism, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Male Hypogonadism and features dormant and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

  • The report provides a snapshot of the global therapeutic landscape of Male Hypogonadism
  • The report reviews pipeline therapeutics for Male Hypogonadism by companies and universities/research institutes based on information derived from company and industry-specific sources
  • The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
  • The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
  • The report reviews key players involved Male Hypogonadism therapeutics and enlists all their major and minor projects
  • The report assesses Male Hypogonadism therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type
  • The report summarizes all the dormant and discontinued pipeline projects
  • The report reviews latest news related to pipeline therapeutics for Male Hypogonadism

Reasons to buy

  • Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Identify and understand important and diverse types of therapeutics under development for Male Hypogonadism
  • Identify potential new clients or partners in the target demographic
  • Develop strategic initiatives by understanding the focus areas of leading companies
  • Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics
  • Devise corrective measures for pipeline projects by understanding Male Hypogonadism pipeline depth and focus of Indication therapeutics
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
  • Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

Table of Contents

  • Table of Contents
    • List of Tables
    • List of Figures
  • Introduction
    • Global Markets Direct Report Coverage
  • Male Hypogonadism Overview
  • Therapeutics Development
    • Pipeline Products for Male Hypogonadism - Overview
    • Pipeline Products for Male Hypogonadism - Comparative Analysis
  • Male Hypogonadism - Therapeutics under Development by Companies
  • Male Hypogonadism - Therapeutics under Investigation by Universities/Institutes
  • Male Hypogonadism - Pipeline Products Glance
    • Late Stage Products
    • Clinical Stage Products
    • Early Stage Products
  • Male Hypogonadism - Products under Development by Companies
  • Male Hypogonadism - Products under Investigation by Universities/Institutes
  • Male Hypogonadism - Companies Involved in Therapeutics Development
    • Antares Pharma, Inc.
    • Clarus Therapeutics, Inc.
    • Endo Pharmaceuticals Inc.
    • EndoCeutics, Inc.
    • Ferring International Center S.A.
    • Forendo Pharma Limited
    • Lipocine Inc.
    • M et P Pharma AG
    • Merck & Co., Inc.
    • Mereo Biopharma Group Plc
    • Millennium Pharmaceuticals Inc
    • Pantarhei Bioscience BV
    • Repros Therapeutics Inc.
    • Variant Pharmaceuticals, Inc.
  • Male Hypogonadism - Therapeutics Assessment
    • Assessment by Monotherapy Products
    • Assessment by Target
    • Assessment by Mechanism of Action
    • Assessment by Route of Administration
    • Assessment by Molecule Type
  • Drug Profiles
    • BGS-649 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • corifollitropin alfa - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • enclomiphene citrate - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • fispemifene - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Kisspeptin-10 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Libidua - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • LPCN-1111 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • MSS-722 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • T-2 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • TAK-448 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • testosterone - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • testosterone - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • testosterone - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • testosterone - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • testosterone - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • testosterone enanthate - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • testosterone undecanoate - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • testosterone undecanoate - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • testosterone undecanoate - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • testosterone undecanoate - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • testosterone undecanoate - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • testosterone undecanoate - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • VAR-100 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
  • Male Hypogonadism - Dormant Projects
  • Male Hypogonadism - Discontinued Products
  • Male Hypogonadism - Product Development Milestones
    • Featured News & Press Releases
      • Jul 06, 2016: Aytu BioScience Provides Update on Natesto Product Launch
      • Jun 30, 2016: Aytu BioScience to Host Conference Call to Detail Company's Natesto U.S. Launch Plans
      • Jun 28, 2016: Aytu BioScience Announces Presentation of Clinical Data Highlighting Efficacy of Natesto (Testosterone) Nasal Gel in Men with Seasonal Allergies
      • Jun 17, 2016: Acerus Announces NATESTO Scientific Abstract Presentation at the 71st Annual Canadian Urological Association Meeting
      • Jun 01, 2016: Repros Provides Update on EU Submission of Enclomiphene for the Treatment of Secondary Hypogonadism and 3 Month Interim Results for Enclomiphene Study in Obese Secondary Hypogonadal Men
      • Jun 01, 2016: Repros Provides Update on EU Submission of Enclomiphene for the Treatment of Secondary Hypogonadism and 3 Month Interim Results for Enclomiphene Study in Obese Secondary Hypogonadal Men
      • Jun 01, 2016: Antares Pharma Announces Phase 3 trail Update on QuickShot Testosterone Clinical Program
      • May 18, 2016: Aytu BioScience Initiates Commercial Expansion to Support July 2016 Launch of Natesto
      • Apr 19, 2016: Transdermal Delivery Solutions Announces Regulatory Approval of Clinical Trials Commencement of Testagen Topical Testosterone HypoSpray
      • Mar 28, 2016: Apricus Reports Top-Line Phase 2b Data for Fispemifene in Symptomatic Secondary Hypogonadism
      • Mar 16, 2016: Antares Pharma Announces Completion of the 52 Week QuickShot Phase 3 Study in Testosterone Deficient Men
      • Mar 15, 2016: Repros Announces Initiation of Formal Approval Process by the European Medicines Agency
      • Feb 16, 2016: Repros Completes Randomization of Enclomiphene Phase 2 Proof of Concept Study in Obese Secondary Hypogonadal Men
      • Feb 08, 2016: Repros Holds Meeting With FDA to Discuss Complete Response Letter for Enclomiphene in the Treatment of Secondary Hypogonadism
      • Feb 02, 2016: Apricus Biosciences to Present at the 18th Annual BIO CEO & Investor Conference and Provide Update on Fispemifene
  • Appendix
    • Methodology
    • Coverage
    • Secondary Research
    • Primary Research
    • Expert Panel Validation
    • Contact Us
    • Disclaimer

List of Tables

  • Number of Products under Development for Male Hypogonadism, H2 2016
  • Number of Products under Development for Male Hypogonadism - Comparative Analysis, H2 2016
  • Number of Products under Development by Companies, H2 2016
  • Number of Products under Investigation by Universities/Institutes, H2 2016
  • Comparative Analysis by Late Stage Development, H2 2016
  • Comparative Analysis by Clinical Stage Development, H2 2016
  • Comparative Analysis by Early Stage Development, H2 2016
  • Products under Development by Companies, H2 2016
  • Products under Development by Companies, H2 2016 (Contd..1)
  • Products under Investigation by Universities/Institutes, H2 2016
  • Male Hypogonadism - Pipeline by Antares Pharma, Inc., H2 2016
  • Male Hypogonadism - Pipeline by Clarus Therapeutics, Inc., H2 2016
  • Male Hypogonadism - Pipeline by Endo Pharmaceuticals Inc., H2 2016
  • Male Hypogonadism - Pipeline by EndoCeutics, Inc., H2 2016
  • Male Hypogonadism - Pipeline by Ferring International Center S.A., H2 2016
  • Male Hypogonadism - Pipeline by Forendo Pharma Limited, H2 2016
  • Male Hypogonadism - Pipeline by Lipocine Inc., H2 2016
  • Male Hypogonadism - Pipeline by M et P Pharma AG, H2 2016
  • Male Hypogonadism - Pipeline by Merck & Co., Inc., H2 2016
  • Male Hypogonadism - Pipeline by Mereo Biopharma Group Plc, H2 2016
  • Male Hypogonadism - Pipeline by Millennium Pharmaceuticals Inc, H2 2016
  • Male Hypogonadism - Pipeline by Pantarhei Bioscience BV, H2 2016
  • Male Hypogonadism - Pipeline by Repros Therapeutics Inc., H2 2016
  • Male Hypogonadism - Pipeline by Variant Pharmaceuticals, Inc., H2 2016
  • Assessment by Monotherapy Products, H2 2016
  • Number of Products by Stage and Target, H2 2016
  • Number of Products by Stage and Mechanism of Action, H2 2016
  • Number of Products by Stage and Route of Administration, H2 2016
  • Number of Products by Stage and Molecule Type, H2 2016
  • Male Hypogonadism - Dormant Projects, H2 2016
  • Male Hypogonadism - Discontinued Products, H2 2016

List of Figures

  • Number of Products under Development for Male Hypogonadism, H2 2016
  • Number of Products under Development for Male Hypogonadism - Comparative Analysis, H2 2016
  • Number of Products under Development by Companies, H2 2016
  • Comparative Analysis by Late Stage Development, H2 2016
  • Comparative Analysis by Clinical Stage Development, H2 2016
  • Assessment by Monotherapy Products, H2 2016
  • Number of Products by Targets, H2 2016
  • Number of Products by Stage and Targets, H2 2016
  • Number of Products by Mechanism of Actions, H2 2016
  • Number of Products by Stage and Mechanism of Actions, H2 2016
  • Number of Products by Routes of Administration, H2 2016
  • Number of Products by Stage and Routes of Administration, H2 2016
  • Number of Products by Molecule Types, H2 2016
  • Number of Products by Stage and Molecule Types, H2 2016
Back to Top